Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | ACR | P10323 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873337 | 0.91 | MAPT (0.51) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL5150469 | 0.89 | MAPT (0.75) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL4869583 | 0.87 | MAPT (0.45) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL4872988 | 0.87 | CYP1A2 (0.54) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL3798740 | 0.86 | MAPT (0.58) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL3802396 | 0.84 | MAPT (0.53) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL5148427 | 0.83 | MAPT (0.54) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL5155141 | 0.83 | MAPT (0.57) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL5150504 | 0.83 | MAPT (0.52) | MAPTALDH1A1KDM4EPOLBMAPK1 | |
| SCHEMBL5150494 | 0.83 | MAPT (0.66) | MAPTALDH1A1KDM4EPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326790-B2 | Diphenylisoxazole compounds and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-7326790-B2 | Diphenylisoxazole compounds and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-7220745-B2 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1641452-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | Rigel Pharmaceuticals (US) | 2006-04-05 | — | — | EP | disclosed |
| EP-1620412-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | Rigel Pharmaceuticals, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | MIDCAP FINANCIAL TRUST | 2004-12-16 | — | — | US | disclosed |
| WO-2004103366-A1 | HETEROCYCLIC COMPOUNDS USEFUL TO TREAT HCV | RIGEL PHARMACEUTICALS (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004099165-A2 | HETEROCYCLIC COMPOUNDS AND HYDRO ISOMERS THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142985-A1 | Heterocyclic compounds useful to treat HCV | HAVCR2, PCNA, HCCS | MAPT 4317/4885ALDH1A1 1236/4885KDM4E 2617/4885 |
| US-20040254227-A1 | Heterocyclic compounds and hydro isomers thereof | HAVCR2, PCNA, HCCS | MAPT 4266/4885ALDH1A1 491/4885KDM4E 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.